Pioglitazone: A New Paradigm in Management of PCOS; An Open Labelled Study
July 2020
in “
Zenodo (CERN European Organization for Nuclear Research)
”
TLDR Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.
This study evaluated the effects of adding pioglitazone to either metformin or spironolactone in 50 women with PCOS over six months. Both treatment groups showed significant improvements in menstrual cycle frequency and Ferriman-Gallwey scores, indicating reduced symptoms of hyperandrogenism. While serum total cholesterol and 2-hour plasma glucose levels showed a nonsignificant decrease, serum total testosterone significantly declined in both groups, with a more pronounced reduction in the pioglitazone and metformin group. Additionally, serum adiponectin levels increased significantly despite an increase in BMI and waist circumference. No major adverse events were reported. The study concluded that pioglitazone, when combined with either metformin or spironolactone, improved metabolic parameters and insulin resistance in women with PCOS, suggesting the need for further randomized trials to confirm these findings.